PMV Pharma Prices $50M Oversubscribed Offering at $1.21, Deep Discount to Market
PMVP sits 17% above its 52-week low of $1.02 on elevated volume (3.6× avg).
Summary
PMV Pharma priced an oversubscribed $50.8 million public offering at $1.21 per share with warrants, a steep discount to the $1.19 market price. The deal includes 22.1 million shares, pre-funded warrants for 19.9 million shares, and accompanying warrants for 42 million shares. The combined offering price of each pre-funded warrant and accompanying warrant is $1.20999. This follows the company's going concern warning and cash runway under one year disclosed in its Q2 10-Q. The offering is highly dilutive, nearly doubling the share count, but provides critical funding ahead of the planned NDA submission for rezatapopt. Closing is expected September 2, 2026.
At the time of this announcement, PMVP was trading at $1.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $64.7M. The 52-week trading range was $1.02 to $1.88. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.